Morgan Stanley’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-10,042,399
| Closed | -$404M | – | 8420 |
|
|
2026
Q1 | $404M | Buy |
10,042,399
+869,395
| +9% | +$18.7M | 0.02% | 616 |
|
|
2025
Q4 | $230M | Sell |
9,173,004
-470,244
| -5% | -$11M | 0.01% | 868 |
|
|
2025
Q3 | $218M | Sell |
9,643,248
-108,953
| -1% | -$2.54M | 0.01% | 877 |
|
|
2025
Q2 | $169M | Buy |
9,752,201
+126,078
| +1% | +$2.33M | 0.01% | 960 |
|
|
2025
Q1 | $211M | Sell |
9,626,123
-1,104
| -0% | -$30.5K | 0.02% | 815 |
|
|
2024
Q4 | $307M | Buy |
9,627,227
+6,237,442
| +184% | +$188M | 0.02% | 648 |
|
|
2024
Q3 | $97.8M | Buy |
3,389,785
+1,270,888
| +60% | +$47.1M | 0.01% | 1260 |
|
|
2024
Q2 | $81.3M | Buy |
2,118,897
+481,279
| +29% | +$21.8M | 0.01% | 1326 |
|
|
2024
Q1 | $96.3M | Sell |
1,637,618
-4,556,664
| -74% | -$290M | 0.01% | 1227 |
|
|
2023
Q4 | $371M | Buy |
6,194,282
+4,585,286
| +285% | +$233M | 0.02% | 809 |
|
|
2023
Q3 | $61.2M | Buy |
1,608,996
+852,331
| +113% | +$37.4M | 0.01% | 1393 |
|
|
2023
Q2 | $68.9M | Buy |
756,665
+3,803
| +0.5% | +$328K | 0.01% | 1320 |
|
|
2023
Q1 | $49.7M | Buy |
752,862
+452,979
| +151% | +$26.1M | 0.01% | 1552 |
|
|
2022
Q4 | $15.5M | Buy |
299,883
+76,607
| +34% | +$4.06M | ﹤0.01% | 2595 |
|
|
2022
Q3 | $15.3M | Sell |
223,276
-229,744
| -51% | -$13.6M | ﹤0.01% | 2496 |
|
|
2022
Q2 | $20.5M | Buy |
453,020
+199,631
| +79% | +$9.1M | ﹤0.01% | 2273 |
|
|
2022
Q1 | $12.9M | Buy |
253,389
+185,730
| +275% | +$8.2M | ﹤0.01% | 2600 |
|
|
2021
Q4 | $3.2M | Sell |
67,659
-109,637
| -62% | -$4.32M | ﹤0.01% | 4181 |
|
|
2021
Q3 | $5.84M | Sell |
177,296
-52,045
| -23% | -$2.92M | ﹤0.01% | 3508 |
|
|
2021
Q2 | $14.5M | Buy |
229,341
+77,317
| +51% | +$3.99M | ﹤0.01% | 2546 |
|
|
2021
Q1 | $6.52M | Buy |
152,024
+51,679
| +52% | +$2.45M | ﹤0.01% | 3133 |
|
|
2020
Q4 | $5.74M | Buy |
100,345
+60,546
| +152% | +$2.56M | ﹤0.01% | 3103 |
|
|
2020
Q3 | $1.2M | Sell |
39,799
-16,591
| -29% | -$496K | ﹤0.01% | 4075 |
|
|
2020
Q2 | $1.84M | Buy |
56,390
+6,730
| +14% | +$216K | ﹤0.01% | 3670 |
|
|
2020
Q1 | $1.33M | Sell |
49,660
-72,887
| -59% | -$2.59M | ﹤0.01% | 3723 |
|
|
2019
Q4 | $3.75M | Sell |
122,547
-289,557
| -70% | -$8.01M | ﹤0.01% | 3498 |
|
|
2019
Q3 | $9.93M | Buy |
412,104
+400,191
| +3,359% | +$11M | ﹤0.01% | 2140 |
|
|
2019
Q2 | $303K | Sell |
11,913
-1,236,481
| -99% | -$25.2M | ﹤0.01% | 4843 |
|
|
2019
Q1 | $24.3M | Buy |
1,248,394
+1,191,729
| +2,103% | +$18.7M | 0.01% | 1314 |
|
|
2018
Q4 | $747K | Sell |
56,665
-3,647
| -6% | -$56K | ﹤0.01% | 4504 |
|
|
2018
Q3 | $1.07M | Sell |
60,312
-19,315
| -24% | -$357K | ﹤0.01% | 4485 |
|
|
2018
Q2 | $1.75M | Buy |
79,627
+59,125
| +288% | +$1.36M | ﹤0.01% | 4201 |
|
|
2018
Q1 | $453K | Buy |
20,502
+1,594
| +8% | +$31.3K | ﹤0.01% | 5063 |
|
|
2017
Q4 | $410K | Buy |
+18,908
| New | +$278K | ﹤0.01% | 5080 |
|
Other funds holding APLS
Morgan Stanley's APLS Position: Q2 2026 in Review
Morgan Stanley sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 10,042,399 shares — an estimated $404M sold.
Morgan Stanley first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $404M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Morgan Stanley reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 10,042,399 Apellis Pharmaceuticals shares in Q2 2026, an estimated $404M.
- Morgan Stanley first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Morgan Stanley's Apellis Pharmaceuticals position peaked at $404M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.